

FORM PTO-1390
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

13170PCTUS

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

Noted as 10/030061

INTERNATIONAL APPLICATION NO.
PCT/IT99/00207INTERNATIONAL FILING DATE
07 July 1999 (07.07.99)PRIORITY DATE CLAIMED
07 July 1999 (07.07.99)

TITLE OF INVENTION

COVALENT DERIVATIVES OF ALKANOLAMIDES OF MONOCARBOXYLIC AND DICARBOXYLIC ACIDS FUNCTIONALLY ACTIVE ON THE CB2 CANNABINOID RECEPTOR

APPLICANT(S) FOR DO/EO/US

COMELLI, Christina; DELLA VALLE, Francesco; DELLA VALLE, Maria Federica; MARCOLONGO, Gabriele

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). **and Power of Attorney**
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☒ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Application Data Sheet
Version with Markings to Show Changes Made
Return Postcard

Certificate of Mailing Under 37 C.F.R. 1.10

I hereby declare that this correspondence is being deposited with the United States Postal Service via Express Mail Label No. EL 84910229 US in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C.

Date: 1/4/02 Name: Fran McHale

U.S. APPLICATION NO (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 890.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	27 - 20 =	7	x \$18.00	\$ 126.00

\$

Independent claims	2 - 3 =	0	x \$84.00	\$ 0
--------------------	---------	---	-----------	------

\$

MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$
---	--	--	------------	----

\$

TOTAL OF ABOVE CALCULATIONS =

\$ 1016.00

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2. +

\$

SUBTOTAL =

\$ 508.00

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 508.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

40.00

TOTAL FEES ENCLOSED =

\$ 548.00

Amount to be
refunded:

\$

charged:

\$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 11-0171 in the amount of \$ 548.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 11-0171. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Milton Springut
Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, NY 10022

SIGNATURE

John J. Santalone

NAME

32,794

REGISTRATION NUMBER

10/030061

PATENT

13170PCTUS

531 Rec'd PCT

04 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith

Examiner: Not yet assigned
Group Art Unit: Not yet assigned

#2/a

For: Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

January 4, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination on the merits, please enter the following amendments in the above-identified application.

IN THE CLAIMS

Please amend claims 2-19 as follows. Please add new claims 20-27:

2. (Amended) A compound according to Claim 1, wherein R2 and R5 are identical to one another.
3. (Amended) A compound according to Claim 1, wherein R3 and R6 are identical to one another.
4. (Amended) A compound according to Claim 1, wherein R1 is a saturated or mono-unsaturated alkyl radical with from 1 to 23 carbon atoms.
5. (Amended) A compound according to Claim 1, wherein R4 is a saturated or mono-unsaturated alkylene radical with from 1 to 20 carbon atoms.

10030061-010402

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith
Page 2

6. (Amended) A compound according to Claim 1, wherein R7, R8 and R9 are alkyl or alkenyl radicals with from 1 to 7 carbon atoms.
7. (Amended) A compound according to Claim 1, wherein R10 is an alkyl radical with from 1 to 20 carbon atoms.
8. (Amended) A compound according to Claim 1, wherein R2 is an alkyl or alkenyl group with from 1 to 7 carbon atoms.
9. (Amended) A compound according to Claim 1, wherein Y is an alkylene radical with from 2 to 20 carbon atoms.
10. (Amended) A compound according to Claim 1, wherein X is a cycloalkyl-ether or thio-ether, having a ring with 5 or 6 members.
11. (Amended) A compound according to Claim 1, wherein R11 or R12 is an alkyl or alkenyl radical with from 1 to 25 carbon atoms.
12. (Amended) A compound according to Claim 1, wherein R7 and R8 form, together with the nitrogen atoms to which they are bound, a ring having from 5 to 7 members.
13. (Amended) A compound according to Claim 1, wherein the -NR12R13 group is selected from the group consisting of: piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl and hydroxyethylpiperazinyl groups.
14. (Amended) A compound according to Claim 1, wherein R14 is an alkylene radical with from 1 to 10 carbon atoms.
15. (Amended) A compound according to Claim 1, wherein R15 is an alkyl or alkenyl radical with from 1 to 7 carbon atoms.

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith
Page 3

16. (Amended) A medicament comprising the compound according to Claim 1.
17. (Amended) A drug with agonist activity in relation to a CB2 cannabinoid receptor comprising the compound according to Claim 16.
18. (Amended) A drug for the treatment of inflammatory processes or inflammatory processes with a hyperalgetic component, each process having a neurogenic basis or an immunogenic basis, each basis being associated with a immuno-inflammatory condition, a neurodegenerative pathological condition, or a pathological condition in which a non-psychomimetic effect of cannabinoids mediated either by CB2 receptors or by peripheral CB1 receptors is noted.
19. (Amended) A cosmetic additive comprising the compound according to Claim 1.
20. (New) A compound according to Claim 4, wherein R1 is a saturated or mono-unsaturated alkyl radical with from 13 to 15 carbon atoms.
21. (New) A compound according to Claim 5, wherein R4 is a saturated or mono-unsaturated alkylene radical with from 6 to 14 carbon atoms.
22. (New) A compound according to Claim 6, wherein R7, R8 and R9 are methyl groups.
23. (New) A compound according to Claim 9, wherein Y is an alkylene radical with 2 to 6 carbon atoms.
24. (New) A compound according to Claim 10, wherein the members are selected from the group consisting of: tetrahydropyran-2-yl, tetrahydrofuran-2-yl, tetrahydrothiopyran-2-yl, tetrahydrothiofuran-2-yl, 4-methoxytetrahydropyran-2-yl, and 1,4-dioxan-2-yl.

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith
Page 4

25. (New) A compound according to Claim 11, wherein R11 or R12 contains from 1 to 5 heteroatoms selected from the group consisting of: sulphur, oxygen and nitrogen.

26. (New) A compound according to Claim 12, wherein the ring contains a further nitrogen atom that is non-substituted or is substituted by a methyl or ethyl group.

27. (New) A compound according to Claim 14, wherein R14 is an alkylene radical with from 2 to 4 carbon atoms.

REMARKS


All of the claims have been amended herein to more clearly and specifically describe Applicants' invention. Entry of this amendment is respectfully requested. New claims have also been added. Support for the new claims is found in the application and claims as originally filed. No new matter is added. Entry of the new claims, and consideration of the application, is respectfully requested.

It is respectfully submitted that this application is now in condition for consideration and examination on the merits. If resolution of any remaining issue is required prior to examination of the application, it is respectfully requested that the Examiner contact Applicants' undersigned attorney at the telephone number provided below.

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith
Page 5

No fee is required in connection with the filing of this Preliminary Amendment. If any fee is deemed necessary, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 11-0171.

Respectfully submitted,


John J. Santalone
Registration No.: 32,794
Attorney for Applicants

Kalow & Springut LLP
Telephone No.: (212) 813-1600

t:\patents\applications\13170\20011228 preliminary amendment.doc

10030061-010402

10/030061

PATENT

13170PCTUS

531 Rec'd PCT

04 JAN 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith

Examiner: Not yet assigned
Group Art Unit: Not yet assigned

For: Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor

Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

January 4, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Sir:

In accordance with 37 CFR § 1.121(c)(1)(ii) applicants submit the following marked-up version of claims corresponding to the amended claims filed herewith:

2. (Amended) [Compounds]A compound according to Claim 1, [in which]wherein R2 and R5 are identical to one another.
3. (Amended) [Compounds]A compound according to Claim 1[or Claim 2], [in which]wherein R3 and R6 are identical to one another.
4. (Amended) [Compounds]A compound according to [any one of Claims 1 to 3]Claim 1, [in which]wherein R1 is a saturated or mono-unsaturated alkyl radical with from 1 to 23 carbon atoms[, preferably from 13 to 15 carbon atoms].
5. (Amended) [Compounds]A compound according to [any one of Claims 1 to 4]Claim 1, [in which]wherein R4 is a saturated or mono-unsaturated alkylene radical with from 1 to 20 carbon atoms[, preferably from 6 to 14 carbon atoms].

Applicant: Comelli *et al.*
Serial No.: Not yet assigned
Filed: Herewith
Page 2

6. (Amended) [Compounds] A compound according to [any one of Claims 1 to 5] Claim 1, [in which] wherein R7, R8 and R9 are [an]alkyl or alkenyl [radial] radicals with from 1 to 7 carbon atoms[, preferably a methyl group].

7. (Amended) [Compounds] A compound according to [any one of Claims 1 to 6] Claim 1, [in which] wherein R10 is an alkyl radical with from 1 to 20 carbon atoms.

8. (Amended) [Compounds] A compound according to [any one of Claims 1 to 7] Claim 1, [in which] wherein R2 is an alkyl or alkenyl group with from 1 to 7 carbon atoms.

9. (Amended) [Compounds] A compound according to [any one of Claims 1 to 8] Claim 1, [in which] wherein Y is an alkylene radical with from 2 to 20 carbon atoms[, preferably from 2 to 6 carbon atoms].

10. (Amended) [Compounds] A compound according to [any one of Claims 1 to 9] Claim 1, wherein, [in which, when] X is a cycloalkyl-ether or thio-ether, [it has] having a ring with 5 or 6 members[, preferably selected from tetrahydropyran-2-yl, tetrahydrofuran-2-yl, tetrahydrothiopyran-2-yl, tetrahydrothiofuran-2-yl, 4-methoxytetrahydropyran-2-yl, or 1,4-dioxan-2-yl].

11. (Amended) [Compounds] A compound according to [any one of Claims 1 to 10] Claim 1, [in which] wherein R11 or R12 [are] is an alkyl or alkenyl radical with from 1 to 25 carbon atoms[possibly containing from 1 to 5 heteroatoms selected from sulphur, oxygen and nitrogen].

12. (Amended) [Compounds] A compound according to [any one of Claims 1 to 11] Claim 1, [in which] wherein R7 and R8 form, together with the nitrogen atoms to which they are bound, a ring having from 5 to 7 members[, possibly containing a further nitrogen atom which is non-substituted or is substituted by a methyl or ethyl group].

10030061-010400

[illegible]

19. (Amended) A cosmetic additive comprising [Use of] the compound[s] according to [anyone of]Claim[s] 1[to 15 as cosmetic additives].

COVALENT DERIVATIVES OF ALKANOLAMIDES OF MONOCARBOXYLIC
AND DICARBOXYLIC ACIDS FUNCTIONALLY ACTIVE ON THE CB2
CANNABINOID RECEPTOR

Field of the invention

The present invention relates to novel covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids with aminoalcohols which can usefully be used as agonists of the CB2 cannabinoid receptor and hence as drugs active in pathological conditions which can be controlled by stimulation and/or costimulation of this receptor.

Prior art

Pharmacological effects of the cannabinoids not on the central nervous system, such as, for example, vascular and endo-ocular hypotensive effects and anti-asthmatic and muscle-relaxant effects have been known for some time but, because of the concomitant psychomimetic effects of these molecules, their therapeutic use is limited to the treatment of very serious pathological conditions such as the cachetic states associated with AIDS and, in any case, in particularly controlled clinical situations

10030061-0104083

(Hollister L.E. Pharmacol. Rev. 1986, 38: 1-20). With regard to the multiplicity of the effects of the cannabinoids, the cell and molecular mechanisms upon which these are based are currently under active investigation.

Recent research has demonstrated the functions of the so-called CB cannabinoid receptors. Of these, the CB1 receptor, which was originally identified in the central nervous system (SNC), and the CB2 receptor, which is located mainly in peripheral cells of the immune system and has recently been found in the T-lymphocytes (Galiegue S. et al. Eur. J. Pharmacol. 1995, 232: 54-61; Munro S. et al. Nature 1993, 365: 61-65; Schatz A. R. et al. Tox. Appl. Pharmacol. 1997, 142: 248-287), have been studied in particular.

It is currently considered that the CB2 receptors can mediate the effects of the cannabinoids on cells of the immune system such as the mast cells and the lymphocytes, by inhibitory modulation of the levels of pro-inflammatory cytokines which are expressed and secreted in excess by these cells when they are hyperactivated by exposure to tissue toxae of various kinds (Matsuda L.A. Cit. Rev. Neurobiol. 1997, 11: 143-146). It is therefore

considered that functional agonists of the CB2 receptor - together with functional agonists of the CB1 receptor which have recently also been found at the level of the peripheral nervous system (Hohmann A.G. et al. 1997 Abstract Soc. Neurosci. 23: 1954; Richardson J.D. et al 1998 J. Neurosci. 18: 451-457) on cells of the immune system (Galiegue S. et al. Eur. J. Pharmacol. 1995, 232: 54-61) and on cells of the monocyte-macrophage line (Berdyshev E.V. et al. Eur. J. Pharmacol. 1997, 330: 231-240) - are essentially assigned the functions of controlling neuro-immuno-inflammatory processes (Richardson J.D. et al. Pain 1998, 75: 111-119; Calignano A. et al. Nature 1998, 394: 277-281). In these conditions, it has been shown that synergic functional activation of the CB2 receptor and of the CB1 receptor brings about maximum control of the neuro-immuno-inflammatory processes, including the hyperalgetic phenomenon which frequently accompanies these processes (Calignano A. et al. Nature 1998, 394: 277-281). This synergy of action results from the simultaneous functional activation of the CB1 and CB2 receptors which are distributed and/or expressed differently, quantitatively, in tissue components functionally connected with one another in a mutual activator-effector relationship, on the basis of the chemical mediators

released thereby under agonist stimulus (Calignano A. et al. Nature 1998, 394: 277-281; Levi-Montalcini R. et al. TINS 1996, 19: 514-520). It has been shown that the neurokine NGF is a fundamental modulator of the neuro-immuno-inflammatory processes triggered by noxae of various kinds, many of the cell populations being involved in these NGF-dependent processes for their survival, maturation, differentiation and gene expression (Levi-Montalcini R. et al. TINS 1996, 19: 514-520). It is in fact known that the receptor - known as trk - which has a high affinity for NGF, is expressed at the level of the peripheral nervous system, of the tissue macrophages, and of various cell lines with an immune character such as mast cells, basophilic cells and lymphocytes. It is also known that these tissue populations also express the cannabinoid receptors CB1 and CB2, although with a different quantitative pattern (Galiegue S. et al. Eur. J. Pharmacol. 1995, 232: 54-61).

Recent results demonstrate a protective role of the CB2 receptor in neurodegenerative processes mediated by excitotoxic amino-acids (Skaper S.D. et al. Proc. Natl. Acad. Sci. U.S.A. 1996, 93: 3984-3989). It has very recently also been discovered that the viral protein gp120 of the HIV virus responsible for AIDS can

stimulate, by interaction with a specific "supersite" which is present in a well-preserved region of the virus and which can thus act as a "superantigene" (Patella V. et al. J. Immunol. 1998, 161: 5647-5655), differential release from the mast cell of specific cytokines - in particular IL4 and IL13 - which in turn are responsible for the maturation and the consequent prevalence of the Th2 cells of the immune system, by means of which the virus finds the best propagation conditions (Marone G. - Paper to the Congress of Rome 5-7 March 1999 - Accademia Nazionale dei Lincei). It has also been shown that the Th2 cells of the immune system (with particular reference to the CD4+ clone) express the trk receptor having a high affinity for NGF and themselves produce NGF as a result of antigenic stimulation (Ehrard P.B. et al. 1993 Proc. Acad. Sci. U.S.A., 90: 10984-10988).

NGF has recently been shown to facilitate and strengthen gene expression and replication of the HIV virus (Ensoli F. et al 1994 (Virology, 200: 668-676). The levels of NGF neurokine in the serum of patients suffering from AIDS are particularly high and play a part in the progress of the disease (Pica F. et al. AIDS 1998, 12: 2025-2029). It has recently been shown that, in conditions of antigenic stimulation, high levels of NGF

strengthen the return, proliferation and tissue differentiation of the circulating monocytes to macrophages. It is also known that macrophages, by means of suitable chemoreceptors, are tissue reservoirs of the virus and elements of increased tropism for the T-lymphocytes at the sites of inflammation where the propagation of HIV is greatly facilitated (Di Marzio P. et al. AIDS Res. H. Retrov. 1998, 14: 129-138; Gurwitz D. et al. Mol. Med. Today 1998, 4: 196-200). It has recently been shown that, as a result of antigenic stimulation, endocannabinoids functionally active at the CB1 and CB2 receptors modulate differentially the expression and/or the secretion of proinflammatory cytokine such as, of example, IL4, by the monocytes/macrophages (Berdishev E.V. et al. Eur. J. Pharmacol. 1997, 330: 231-240). It is also known that, not only the serum levels, but also the tissue levels of NGF are particularly high during neuro-immuno-inflammatory processes (Levi-Montalcini R. TINS 1996, 19: 514-520). The mast cell is the seat of synthesis, storage and release of biologically active NGF which is readily released by the mast cell in response to neurogenic and immunogenic stimuli (Leon A. et al. Proc. Natl. Acad. Sci. U.S.A., 91: 3739-3743). Both the antigenic stimulus represented by the viral protein

gp120, and also the neurogenic stimulus represented by the substance P which is released at endothelial level in conditions of exposure to the HIV virus (Annunziata P. et al AIDS 1998, 12: 2377-2385) are activators of mast cell hyper-degranulation. In conditions of mast cell hyper-activation, the sensitization of NGF-mediated noxiocptive fibres with an increase in the levels of substance P released at the level of the peripheral nerve endings is known. It is known that this transmitter release may take place orthodromically by axonal reflex, or directly at peripheral level by means of an endogenic ligand not yet identified (Biro T. et al. J. Invest. Dermatol. 1997, 2: 56-60), owing to the activation of suitable vanilloid receptors - known as VRs - located both at the nerve endings and directly on the mast cell (Biro T. et al. Blood 1998, 91: 1332-1340).

In conditions of mast cell hyperactivation by neurogenic and immunogenic stimulus it is also known that the functional activation of the CB2 receptor expressed by the mast cell brings about an inhibitory modulation of the expression and of the secretion of mediators contained therein (Facci L. et al. Proc. Natl. Acad. Sci. U.S.A. 1995, 92: 3376-3380). It is also known that the functional activation of the CB1 receptor by N-

acetylvanillin amide molecules reduces the sensitization induced by NGF on specific cell lines which coexpress the cannabinoid CB1 receptor (Bisogno T. et al. 1998 Patent No. MI98A002064). It has also been shown that this desensitization depends on an inhibitory modulation of the levels of trk receptor expressed by the specific cell lines by the above-mentioned N-acetylvanillin amide molecules (Di Marzo et al. PNAS 1999, submitted). These N-acetylvanillin amide molecules, which are functional agonists of the CB1 receptor, given their chemical construction, also bring about a functional occupation of the vanilloid receptor VR which results in a significant strengthening of the NGF desensitizing effect brought about by the functional activation of the CB1 receptor by means of N-acetylvanillin amide (Di Marzo et al PNAS, 1999, submitted).

Up to now, neither the activity of molecules functionally agonistic to the CB2 receptor and of molecules functionally agonistic to the CB1 receptor, nor the synergy between these actions at the level of the interactions between mast cells and the Th2 lymphocytes resulting from the stimulation induced by the viral protein gp120 on the mast cell has been known. It has recently been discovered that molecules with an N-

acylvanillin amide-type structure which have been found to be capable of acting as functional agonists of the peripheral cannabinoid receptor CB1, have strongly synergic activity with molecules which can act as functional agonists of the CB2 receptor expressed by the mast cell (Bisogno T. et al. Italian patent application No. MI98A002064), such as the molecules discovered by the inventors of this patent.

It is also known that the bioavailability of compounds with poor solubility both in an aqueous environment and in a lipid environment - an essential element for the purposes of the manifestation of a biologically important effect - is often very limited and variable and in any case such as to constitute a problem to be evaluated with care with a view to their use for therapeutic purposes.

Bioavailability is in fact influenced by various factors and, in the first place, by the chemical and physical characteristics of the compound. The size of the molecule, its charge, its ability to bind to or mix with endogenous compounds such as biliary salts, plasma proteins or plasma or lymphatic lipids, its stability in the acid pH of the gastric juices are, for example, among the factors which may greatly influence the

bioavailability of a compound.

More generally, a certain degree of solubility in an aqueous medium favours both their rapid dissolving in the biological fluids and their subsequent contact with the cell membranes, through which they then diffuse as a result of active or passive transportation processes; water-solubility alone, however, does not *per se* ensure optimal bioavailability.

In order to achieve this object, a compound must also have a certain degree of lipo-solubility to enable it to have an efficient interaction with the cell plasma membranes which constitute barriers to be crossed by passive diffusion. In fact, since, in the tissues, there is a system of "solvents" formed by lipids of the cell membranes and by the interstitial and cytoplasmic liquids, absorption represents an extremely complex process which is dependent on the chemical and physical characteristics of the compound; although, on the one hand, lipo-solubility favours the passage of the compound through the cell membranes, on the other hand, this passage is controlled and is dependent proportionally on the concentration of the compound in the aqueous phase, which is also partly correlated with its ability to

ionize in a physiological medium.

Summary of the invention

The inventors of the present patent application have now found that novel covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids with aminoalcohols can usefully be used as drugs with lipid/water partition coefficients and/or with solubility levels which are clearly favourable to interaction with biological membranes. In the novel covalent derivatives of the invention, which have been found to be surprisingly stable, the hydrogen of the alcoholic residue of the alkanolamine is substituted by specific groups which can give a covalent bond with the oxygen.


The novel drugs have been found to be functionally active, as such, on the CB2 cannabinoid receptor, whereas they are inactive on the CB1 receptor. A clear synergy of action between the said compounds and molecules of an N-acylvainillin amide character which are functionally active on the CB1 receptor has also been shown.

A further subject of the present invention is the use of the above-mentioned novel covalent compounds - alone or

in association with N-acylvanillin amide molecules active on the peripheral CB1 receptor - for the preparation of pharmaceutical compositions for human and veterinary use, which are effective for the treatment of the following pathological conditions: immuno-inflammatory conditions of various tissue regions, neurodegenerative conditions, conditions due to the spread of opportunistic viruses, as well as pathological conditions in which a non-psychomimetic effect of cannabinoids is noted; and their compositions for administration by various routes, including the parental, endovenous, intramuscular and subcutaneous routes, the gastroenteric route, the topical skin and mucous-membrane routes, and transdermal, ophthalmic and naso-pulmonary routes.

Detailed description of the invention

The present invention relates to compounds of the general formula (I):




their enantiomers, diastereoisomers, racemates and mixtures thereof, in which:

(a) R1 may be

(1) a linear or branched alkyl radical, saturated or with from 1 to 6 double bonds, a monocyclic or polycyclic alkyl or alkenyl radical, or an aryl, arylalkyl or heterocyclic radical having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, acylamide, keto, nitro, alkoxy, halogen, mercapto, alkylthio, alkyldithio or aryldithio, $-N^+R_7R_8R_9 Z^-$, in which R7, R8 and R9 are identical to one another or different and may be alkyl, alkenyl or arylalkyl radicals and Z^- is the anion of a pharmaceutically acceptable organic or inorganic acid;


(2) a group of formula (II):



in which R4 is a linear or branched alkylene radical saturated or with from 1 to 6 double bonds, a cycloalkylene or cycloalkenylene radical, or an aryl, arylalkyl or heterocyclic diradical with one or more heteroatoms, the radicals optionally being substituted

with one or more groups selected from hydroxy, acylamide, keto, nitro, alkoxy, halogen, mercapto, alkylthio, alkyldithio, or aryldithio, R5 and R6 have the meanings given below for R2 and R3, respectively, or R5 is a group of formula -Y-OH, where Y has the meaning described below in point (c);

(3) a group of formula (III):




in which R4 has the meanings described above and R10 is hydrogen or a linear or branched alkyl radical or an arylalkyl radical, in which, when R10 is hydrogen, the resulting carboxylic group may optionally be salified with an organic or inorganic base to form a pharmaceutically acceptable salt;

(b) R2 is selected from hydrogen or an alkyl, alkenyl or arylalkyl radical;

(c) R3 is a group of formula (IV):

15




in which:

Y is a linear or branched alkylene radical, optionally substituted with one or more phenyl groups, possibly substituted with one or more hydroxy and/or alkoxy groups;

X is selected from:

(1) the radical of a cycloalkyl-ether or cycloalkylthio-ether with a ring of from 3 to 7 members, possibly substituted and possibly comprising a second heteroatom;

(2) a group of formula (V):




in which R₁₁ is selected from: a linear or branched alkyl or alkenyl radical, possibly containing from 1 to 5 heteroatoms, which may be identical to one another or different, a monocyclic or polycyclic alkyl radical, an

40030061 0104083

arylalkyl radical, an aryl radical or a heterocyclic radical which is aromatic or completely or partially saturated, having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, amino, acylamino, keto, ureide, guanidino, nitro, alkoxy, halogen, $-O-PO_3H_2$, $-O-PO_2H_2$, $-O-SO_3H$, $-SO_3H$, mercapto, alkylthio, alkylldithio, arylldithio, azido, $-NHR_9$, $-NR_7R_8$, $-N^+R_7R_8R_9 Z^-$, in which Z^- is the anion of a pharmaceutically acceptable organic or inorganic acid and R_7 , R_8 and R_9 are as defined above, or R_7 and R_8 may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members, possibly containing other heteroatoms selected from oxygen, sulphur and nitrogen, the nitrogen possibly being substituted by an alkyl, benzyl or hydroxyethyl radical, and in which the basic and acid groups present in the molecule may possibly be salified with organic or inorganic acids and bases, respectively, to form pharmaceutically acceptable salts;

(3) a group of formula (VI):




in which:

(i) R12 is selected from: a linear or branched alkyl or alkenyl radical possibly containing from 1 to 5 heteroatoms which may be identical to one another or different, a monocyclic or polycyclic alkyl radical, an arylalkyl radical, an aryl radical or a heterocyclic radical which is aromatic, or completely or partially saturated, having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, amino, acylamino, keto, ureide, guanidino, nitro, alkoxy, $-O-C_6H_4-W$, halogen, $-O-PO_3H_2$, $-O-PO_2H_2$, $-O-SO_3H$, $-SO_3H$, mercapto, alkylthio, alkylldithio, arylldithio, azido, $-NHR_9$, $-NR_7R_8$, $-N^+R_7R_8R_9 Z^-$, in which Z^- is the anion of a pharmaceutically acceptable organic or inorganic acid, and R7, R8 and R9 are as defined above or R7 and R8 may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members, possibly containing other heteroatoms selected from oxygen, sulphur and nitrogen, possibly substituted with an alkyl, benzyl or hydroxyethyl radical, in which W is selected from hydrogen, alkyl, alkoxy, nitro, halogen and hydroxy, and in which the basic and acid groups present in the molecule may possibly be salified with organic or

inorganic acids and bases, respectively, to form pharmaceutically acceptable salts; and


R13 has, independently, the meanings of R12, or may be hydrogen;

(4) a group of formula (VII):



in which R14 is selected from: a linear or branched alkylene or arylalkylene radical, possibly substituted with a hydroxy group or -O-CO-R15, in which R15 is an alkyl, alkenyl or arylalkyl radical, R7, R8 and R9 are as defined above, or R7 and R8 may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members as defined above, and Z⁻ is a pharmaceutically acceptable inorganic or organic anion;

(5) a group of formula (VIII):



in which the $-\text{SO}_3^-$ group may be in the ortho, meta or para position relative to the keto group, and M^+ is a pharmaceutically acceptable inorganic or organic cation.

If R2 and R5 are both present on the same molecule, they are preferably identical to one another.

If R3 and R6 are both present on the same molecule, they are preferably identical to one another.

When R1 is an alkyl radical, it is preferably saturated or mono-unsaturated. It preferably has from 1 to 23 carbon atoms, more preferably from 11 to 17 carbon atoms and even more preferably from 13 to 15 carbon atoms.

When R4 is an alkylene radical, it is preferably saturated or mono-unsaturated. It preferably has from 1 to 20 carbon atoms, even more preferably from 6 to 14 carbon atoms.

When R7, R8 or R9 is an alkyl or alkenyl radical, it

preferably has from 1 to 7 carbon atoms. Even more preferably R7, R8 and R9 are identical to one another and are methyl groups.

When R10 is an alkyl radical, it preferably has from 1 to 20 carbon atoms.

When R10 is hydrogen and the resulting carboxyl group is salified, it is preferably a lithium, sodium, potassium, calcium, magnesium, zinc, copper, ammonium, or mono-, di-, tri- or tetra-alkyl ammonium salt. In the latter case, preferred bases for the salification are mono-ethanolamine, N-(2-hydroxyethyl)dimethyl ammonium, choline or amino-acids amongst which lysine is preferred.

When R2 is an alkyl or alkenyl group, it preferably has from 1 to 7 carbon atoms.

When Y is an alkylene radical, it preferably has from 2 to 20 carbon atoms, even more preferably from 2 to 6 carbon atoms.

When X is a cycloalkyl-ether or a thio-ether, it preferably has a ring with 5 or 6 members, even more preferably, it is selected from tetrahydropyran-2-yl,

tetrahydrofuran-2-yl, tetrahydrothiopyran-2-yl,
tetrahydrothiofuran-2-yl, 4-methoxytetrahydropyran-2-yl,
or 1,4-dioxan-2-yl.

When R11 or R12 is an alkyl or alkenyl radical, it preferably has from 1 to 25 carbon atoms.

When R11 or R12 is an alkyl or alkenyl radical containing from 1 to 5 heteroatoms, these heteroatoms are preferably selected from sulphur, oxygen and nitrogen.

When R7 and R8 form, together with the nitrogen atoms to which they are bound, a ring, the ring preferably has from 5 to 7 members. When the ring contains a further nitrogen atom and this nitrogen atom is substituted by an alkyl radical, it is preferably a methyl or an ethyl group.

When the -NR12R13 group is the residue of a cyclic amine, this amine is preferably selected from piperidine, pyrrolidine, morpholine, piperazine and hydroxyethylpiperazine.

When R14 is an alkylene radical, it preferably has from 1 to 10 carbon atoms, more preferably from 2 to 4 carbon

atoms.

When R15 is an alkyl or alkenyl radical, it preferably has from 1 to 7 carbon atoms.

Z⁻ is preferably selected from chloride, bromide, sulphate, methane sulphonate, hydrogen phosphate, benzene sulphonate, p-toluene sulphonate, acetate, succinate and benzoate.

M⁺ is preferably selected from the following cations: lithium, sodium, potassium, calcium, magnesium, zinc, copper, ammonium, mono-, di-, tri- or tetra-alkyl ammonium, more preferably monoethanol ammonium, N-(2-hydroxyethyl) dimethyl ammonium, or cations of choline or of an amino-acid, preferably lysine.

The term "acylamino" preferably means an acetylamino group.

The term "alkoxy" preferably means a methoxy group.

The term "halogen" preferably means chloro, bromo, iodo or fluoro.

The term "pharmaceutically acceptable acid" preferably means an acid selected from hydrochloric, sulphuric, phosphoric, methane sulphonc, benzene sulphonc, p-toluene sulphonc, acetic, succinic and benzoic acid.

The term "pharmaceutically acceptable base" preferably means a base which can form a lithium, sodium, potassium, calcium, magnesium, zinc, copper, ammonium, or mono-, di-, tri- or tetra-alkyl ammonium salt. In the latter case the base is preferably monoethanolamine, N-(2-hydroxyethyl)dimethyl amine, choline or an amino-acid, most preferably lysine.

The term "arylalkyl radical" preferably means a C₇-C₁₀ arylalkyl radical, more preferably a benzyl group.

The term "aryl radical" preferably means a C₆-C₁₀ aryl radical, more preferably a phenyl group.


The term "heterocyclic radical" preferably means the radical of a saturated, unsaturated or aromatic heterocycle with a ring having 5 or 6 members, more preferably selected from tetrahydrofuran, tetrahydropyran, dioxane, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, N-

methylnpiperazine, pyrrole, thiophene, furan, pyrazole, imidazole, thiazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, quinoline, isoquinoline, indole, benzoimidazole, benzothiazole.

The term "cycloalkyl radical" or "cycloalkenyl radical" preferably means a ring with from 3 to 10 carbon atoms, more preferably 5 or 6 carbon atoms,

Preparation of the compounds of the invention

The compounds of the invention may be prepared by reacting an intermediate of formula (Ia):



in which R, R2 and Y are as defined above, with a compound of formula X', where X' is selected from:



in which n is 0 or a whole number between 1 and 4,;

- Alg-COOR11, in which Alg is selected from chloro, bromo

and iodo and R11 is as defined above;

- R12-N=C=O or R12R13N-CO-Alg, in which R12, R13 and Alg are as defined above;

- Alg-CO-R14-N⁺R7R8RR9 Z⁻, in which R7, R8, R9, R14, Z⁻ and Alg are as defined above; and

- Alg-CO-Ph-SO₃⁻ M⁺, in which M⁺ and Alg are as defined above.

The reaction for the condensation of the intermediates of formula (Ia) with the compounds X' is generally carried out in an inert solvent and preferably at a temperature of between -10°C and the boiling point of the solvent used.

An organic base such as, for example, a tertiary amine, or an inorganic base such as a carbonate or a bicarbonate of an alkali-metal or alkaline-earth metal may also advantageously be used.

Alternatively, when the compound X' contains a carbonyl group which is intended to react with the hydroxyl group of the intermediate (Ia), this carbonyl group may be

activated for condensation in known manner, for example, by transforming it into a hydroxysuccinimide ester or into a mixed anhydride, or by carrying out the condensation reaction in the presence of a condensing agent such as a carbodiimide.

The compounds X' are known and/or commercially available or may be prepared from known and/or commercially available products in accordance with methods well known to an expert in the art.

The compounds of formula (Ia) can be prepared as described in EP 0 550 008, EP 0 550 006 and EP 0 570 714 which are incorporated herein by reference.

The preparation of the compounds of formula (I) is further described by the following preparation examples.

Example 1: Preparation of N-[2-(ethoxycarbonyl)oxyethyl]hexadecanamide (PEA-EC)

3.0 g of N-(2-hydroxyethyl) hexadecanamide (10 mmoles) was dissolved in 75 ml of tetrahydrofuran (THF) at 45°C with stirring. 1.11 g of N-methylmorpholine (11 mmoles) and 1.19 g of ethyl chloroformate (11 mmoles) were added

and the resulting mixture was stirred for a further 3 hours at ambient temperature. The mixture was then evaporated to dryness under vacuum. The residue was taken up with 50 ml of water and extracted 3 times with 30 ml of ethyl acetate; the organic phases were washed twice with 20 ml of water, recombined and evaporated to dryness. The residue was crystallized from 30 ml of tert-butylmethyl ether. The crystallizate was separated by filtration, washed twice with 5 ml of cold tert-butylmethyl ether and finally dried under a high degree of vacuum. The yield of the reaction was 93%.

The product N-[2-ethoxycarbonyloxyethyl] hexadecanamide had the following chemical and physical characteristics:

empirical formula:	$C_{21}H_{41}NO_4$
formula weight:	371.57
elemental composition:	C=67.88%; H=11.12%; N=3.77%, O=17.22%
solubility in water:	slightly soluble
solubility in organic solvents:	10 mg/ml in ethanol, ethyl acetate and n-octanol
melting point:	71-73°C
TLC in 100% ethyl acetate:	Rf=0.62

TLC in heptane/isopropanol/

ethyl acetate/water

(40:20:50:2):

Rf=0.70

Example 2: Preparation of N-[2-(isobutyloxycarbonyl)oxyethyl] hexadecanamide (PEA-IBC)

3.0 g of N-[2-hydroxyethyl]hexadecanamide (10 mmoles) was dissolved in 75 ml of tetrahydrofuran (THF) at 45°C with stirring. 1.11 g of N-methylmorpholine (11 mmoles) and 1.502 g of isobutyl chloroformate (11 mmoles) were added and the resulting mixture was stirred for a further 3 hours at ambient temperature. The mixture was then evaporated to dryness under vacuum. The residue was taken up with 50 ml of water and extracted 3 times with 30 ml of ethyl acetate; the organic phases were washed twice with 20 ml of water, recombined and evaporated to dryness. The residue was crystallized from 30 ml of cold tert-butylmethyl ether and finally dried in a high degree of vacuum. The yield of the reaction was 95%.

The product, N-[2-(isobutyloxycarbonyl)oxyethyl] hexadecanamide had the following chemical and physical characteristics:

29

empirical formula: $C_{23}H_{45}NO_4$
formula weight: 399.62
elemental composition: C=69.13%; H=11.35%;
N=3.50%; O=16.02%
solubility in water: slightly soluble
solubility in 1 mg/ml in ethyl
organic solvents: acetate, 10 mg/ml in
ethanol, and
n-octanol, hot
melting point: 65-67°C
TLC in 100% ethyl acetate: $R_f=0.66$
TLC in heptane/isopropanol/
ethyl acetate/water
(40:20:50:2): $R_f=0.73$

Example 3: Preparation of N-[3-(ethoxycarbonyloxypropyl)]
hexadecanamide (PPA-EC)

3.14g of N-(3-hydroxypropyl) hexadecanamide (10 mmoles) was suspended in 75 ml of tetrahydrofuran (THF) at 45°C with stirring. 1.11 g of N-methylmorpholine (11 mmoles) and 1.19 g of ethyl chloroformate (11 mmoles) were added and the resulting mixture was stirred for a further 3 hours at ambient temperature. The mixture was then evaporated to dryness under vacuum. The residue was

taken up with 50 ml of water and extracted 3 times with 30 ml of ethyl acetate; the organic phases were washed twice with 20 ml of water, recombined and evaporated to dryness. The residue was crystallized from 30 ml of tert-butylmethyl ether. The crystallizate was separated by filtration, washed twice with 5 ml of cold tert-butylmethyl ether and finally dried in a high degree of vacuum. The yield of the reaction was 92%.

The product, (N-[3-)ethoxycarbonyl)oxypropyl] hexadecanamide had the following chemical-physical characteristics:

empirical formula:	$C_{22}H_{43}NO_4$
formula weight:	385.59
elemental composition:	C=68.53%; H=11.24%; N=3.63%; O=16.60%
solubility in water:	slightly soluble
solubility in organic solvents :	10 mg/ml in ethanol, ethyl acetate and n-octanol
melting point:	66-68°C
TLC in 100% ethyl acetate:	Rf=0.61
TLC in heptane/isopropanol/ ethyl acetate/water	

(40:20:50:2):

Rf=0.68

Example 4: Preparation of N,N¹-bis[2-(ethoxycarbonyl)oxyethyl] nonandiamide (ADM-EC)

1.37 g of N,N¹-bis (2-hydroxyethyl) nonandiamide (5 mmoles) was dissolved in 20 ml of anhydrous pyridine. The solution was cooled to 4°C and supplemented with 1.19 g of ethyl chloroformate (11 mmoles); the resulting mixture was stirred for 1 hour at 4°C and then for 3 hours at ambient temperature. The mixture was then evaporated to dryness under vacuum. The residue was taken up with 50 ml of water and extracted 3 times with 30 ml of ethyl acetate; the organic phases were washed twice with 10 ml of water, recombined and evaporated to dryness. The residue was crystallized twice, first from 20 ml of ethyl acetate and then from 20 ml of tert-butylmethyl ether. The crystallizate was separated by filtration, washed twice with 5 ml of cold tert-butylmethyl ether, and finally dried in a high degree of vacuum. The yield of the reaction was 88%.

The product, N,N¹-bis[2-(ethoxycarbonyl)oxyethyl] nonandiamide had the following chemical and physical characteristics:

empirical formula: $C_{19}H_{34}N_2O_8$
formula weight: 418.5
elemental composition: C=54.53%; H=8.19%;
N=6.69%; O=30.59%
solubility in water: slightly soluble
solubility in 10 mg/ml in ethanol,
organic solvents: DMSO
melting point: 78-80°C
TLC in 100% ethyl acetate: $R_f=0.75$
TLC in toluene/ethanol/
acetic acid (63:30:5): $R_f=0.52$

Example 5: Preparation of N-[2-benzylaminocarbonyl)oxyethyl] hexadecanamide (PEA-BCM)

3.0 g of N-(2-hydroxyethyl) hexadecanamide (10 mmols) was suspended in 60 ml of anhydrous toluene; the mixture was stirred and heated with refluxing of the solvent onto anhydrous 4 Å molecular sieves with recycling. 3.0 ml of benzylisocyanate was added and the resulting mixture was heated with refluxing for 6 hours. 2 ml of methanol was then added and the heating to temperature was continued for a further hour. The product crystallized as a result of cooling to ambient temperature. The crystallizate was

separated by filtration, washed twice with 5 ml of cold toluene and finally dried under a high degree of vacuum. The yield of the reaction was 94%.

The product, N-[2-benzylaminocarbonyl)oxyethyl] hexadecanamide had the following chemical and physical characteristics:

empirical formula:	$C_{26}H_{44}N_2O_3$
formula weight:	432.65
elemental composition:	C=72.18%; H=10.25%; N=6.48%; O=11.09%
solubility in water:	slightly soluble
solubility in organic solvents:	10 mg/ml in ethyl acetate and n-octanol, hot
melting point:	126.5-128.5°C
TLC in 100% ethyl acetate:	R _f =0.47
TLC in heptane/isopropanol/ethyl acetate/water (40:20:50:2):	R _f =0.65

Example 6: Preparation of N-[2-(ethoxycarbonylmethyl)aminocarbonyl]oxyethyl hexadecanamide (PEA-EGC)

3.0 g of N-(2-hydroxyethyl) hexadecanamide (10 mmoles) was suspended in 60 ml of anhydrous toluene; the mixture was stirred and heated with refluxing of the solvent onto 4 Å molecular sieves with recycling. 3.0 g of ethyl isocyanate acetate was added and the resulting mixture was heated with refluxing for 6 hours. The mixture was then cooled to 4°C. The crystallize formed was separated by filtration and crystallized from 20 ml of toluene, cold; it was then separated again by filtration, washed twice with 5 ml of cold toluene and finally dried in a high degree of vacuum. The yield of the reaction was 92%.

The product, N-[2-[(ethoxycarbonylmethyl)aminocarbonyl]oxyethyl] hexadecanamide had the following chemical and physical characteristics:

empirical formula:	$C_{23}H_{44}N_2O_5$
formula weight:	428.62
elemental composition:	C=64.45%; H=10.35%; N=6.54%; O=18.66%
solubility in water:	slightly soluble
solubility in organic solvents:	10 mg/ml in ethanol, n-octanol, hot
melting point:	105-106°C

TLC in 100% ethyl acetate: Rf=0.40

TLC in heptane/isopropanol/
ethyl acetate/water

(40:20:50:2): Rf=0.58

Example 7: Preparation of N-[2-[(2-piperidinoethoxy)
carbonylloxyethyl] hexadecanamide (PEA-PEC)

3.0 g of N-(2-hydroxyethyl) hexadecanamide (10 mmoles) was dissolved in 60 ml of tetrahydrofuran (THF) in an anhydrous N₂ atmosphere. 1.11 g of N-methylmorpholine (11 mmoles) was added and the mixture was further supplemented with 1.88 g of (2-bromoethyl) chloroformate (10 mmoles) slowly, dropwise, over a period of 30 minutes. The resulting mixture was kept at ambient temperature with stirring for a further 3 hours and then evaporated to dryness. The residue was taken up with 20 ml of water and extracted 3 times with 20 ml of ethyl acetate. The organic phases were washed twice with 20 ml of water, recombined and evaporated to dryness. The residue was taken up with 50 ml of anhydrous tetrahydrofuran and supplemented with 1.70 g of piperidine (20 mmoles). The mixture was heated to reflux with stirring for 6 hours; it was then cooled to ambient

10030061-010408

temperature and supplemented with 20 ml of water and 60 ml of ethyl acetate. The aqueous phase was discarded, the organic phase was washed with 10 ml of cold 2M NH_3 solution and then with 20 ml of cold water. The aqueous phases were discarded and the organic phase was evaporated to dryness. The residue was crystallized from 30 ml of ethyl acetate, cold. The crystallizate was separated by filtration, washed twice with 5 ml of cold ethyl acetate and finally dried under a high degree of vacuum. The yield of the reaction was 89%.

The product, N-[2-[(2-piperidinoethoxy)carbonyl]oxyethyl] hexadecanamide had the following chemical and physical characteristics:

empirical formula:	$\text{C}_{26}\text{H}_{50}\text{N}_2\text{O}_4$
formula weight:	454.70
elemental composition:	C=68.68%; H=11.08%; N=6.16%; O=14.08%
solubility in water:	slightly soluble
solubility in organic solvents:	10 mg/ml in ethanol,
melting point:	65-67°C
TLC in 100% ethyl acetate:	Rf=0.05
TLC in toluene/ethanol/	

acetic acid (65:30:5):

Rf=0.11

Example 8: Preparation of N-[2-[(2-piperidinoethoxy)-
carbonyl]oxyethyl] hexadecanamide methane sulphonate
(PEA-PECMetS)

4.5 g of N-[2-[(2-piperidinoethoxy)carbonyl]oxyethyl] hexadecanamide was dissolved in 50 ml of anhydrous ethanol and supplemented with 0.96 g of methane sulphonic acid, cold. The mixture was evaporated to dryness and the residue was taken up with 100 ml of distilled water. The solution was frozen and lyophilized.

The product, N-[2-[(2-piperidinoethoxy)carbonyl]oxyethyl] hexadecanamide methane sulphonate had the following chemical and physical characteristics:

empirical formula:	$C_{27}H_{54}N_2O_7S$
formula weight:	550.82
elemental composition:	C=58.88%; H=9.88%; N=5.09%; O=20.23% S=5.82%
solubility in water:	10 mg/ml
solubility in	10 mg/ml in ethanol
organic solvents:	and DMSO

melting point: n.d.

TLC in toluene/ethanol/

acetic acid (65:30:5): Rf=0.11 -

Example 9: Preparation of the tetrahydrofuranyl ether of
N-(2-hydroxyethyl) hexadecanamide (PEA-THF)

3.0 g of N-(2-hydroxyethyl) hexadecanamide (10 mmoles) was suspended in 20 ml of 2,3-dihydrofuran and cooled to 4°C. The mixture was supplemented with 200 mg of pyridinium methane sulphonate with continuous stirring and then heated to 50°C for 60 minutes. The mixture was brought to ambient temperature, supplemented with 50 ml of ethyl acetate and extracted twice with 10 ml of cold water. The aqueous phases were separated and discarded and the organic phase was evaporated to dryness under vacuum. The residue was crystallized from 20 ml of tert-butylmethyl ether. The crystallizate was separated by filtration, washed twice with 4 ml of cold tert-butylmethyl ether and finally dried under a high degree of vacuum. The yield of the reaction was 90%.

The product, the tetrahydrofuranyl ether of N-(2-hydroxyethyl) hexadecanamide had the following chemical and physical characteristics:

empirical formula: $C_{22}H_{43}NO_3$
formula weight: 369.59
elemental composition: C=71.50%; H=11.73%;
N=3.97%; O=12.99%
solubility in water: slightly soluble
solubility in 10 mg/ml in ethanol
organic solvents: and DMSO
melting point: 63-65°C
TLC in 100% ethyl acetate: $R_f=0.41$

TLC in heptane/isopropanol/
ethyl acetate/water
(40:20:50:2): $R_f=0.62$

Example 10: Preparation of the tetrahydrofuranyl ether
of N,N¹-bis(2-hydroxyethyl) nonandiamide (ADM-THF)

1.37 g of N,N¹-bis (2-hydroxyethyl) nonandiamide (5
mmoles) was suspended in 6 ml of 2,3-dihydrofuran. The
mixture was stirred at 4°C and supplemented with 60 mg of
pyridinium methane sulphonate; the mixture was then
heated to 50°C for 60 minutes. The mixture was then
cooled to ambient temperature, supplemented with 30 ml of

ethyl acetate and extracted twice with 5 ml of cold water. The aqueous phases were separated and discarded and the organic phases were evaporated to dryness under vacuum. After thorough drying in a high degree of vacuum, the residue was dispersed cold with 5 ml of tert-butylmethyl ether. The powdery solid thus obtained was separated by filtration, washed twice with 2 ml of cold tert-butylmethyl ether and finally dried under a high degree of vacuum. The yield of the reaction was 94%.

The product, the tetrahydrofuranyl ether of N,N¹-bis(2-hydroxyethyl) nonandiamide had the following chemical and physical characteristics:


empirical formula:	$C_{21}H_{38}N_2O_6$
formula weight:	414.55
elemental composition:	C=60.84%; H=9.24%; N=6.76%; O=23.16%
solubility in water:	10 mg/ml in water
solubility in organic solvents:	10 mg/ml in ethanol and DMSO
melting point:	58-60°C
TLC in acetonitrile/water (9:1)	R _f =0.52
TLC in toluene/ethanol/ acetic acid (65:30:5):	R _f =0.44

Example 11: Preparation of the tetrahydropyranyl ether of N-(2-hydroxyethyl) hexadecanamide (PEA-THP)

3.0 g of N-bis(2-hydroxyethyl) hexadecanamide (10 mmoles) was suspended in 20 ml of 3,4-dihydropyran and cooled to 4°C. 200 mg of pyridinium methane sulphonate was added and the mixture was stirred at 50°C for 60 minutes. The mixture was then brought to ambient temperature, supplemented with 50 ml of ethyl acetate and extracted twice with 10 ml of cold water. The aqueous phases were separated and discarded and the organic phase was evaporated to dryness with rotation. The residue was taken up with 20 ml of petroleum ether and crystallized. The crystallizate was separated by filtration, washed twice with 4 ml of cold petroleum ether and finally dried in a high degree of vacuum. The yield of the reaction was 93%.

The product, the tetrahydropyranyl ether of N-(2-hydroxyethyl) hexadecanamide had the following chemical and physical characteristics:

empirical formula:



formula weight:

383.62

elemental composition: C=70.01%; H=11.824%;
N=3.65%; O=12.51%

solubility in water: slightly soluble

solubility in 10 mg/ml in ethyl
organic solvents: acetate and n-octano

melting point: 52.5-54.5°C

TLC in 100% ethyl acetate R_f=0.43

TLC in heptane/isopropanol/
ethyl acetate/water
(40:20:50:2): R_f=0.65

Example 12: Preparation of the tetrahydropyranyl ether
of N,N'-bis(2-hydroxyethyl) nonandiamide (ADM-THP)

1.37 g of N,N'-bis(2-hydroxyethyl) nonandiamide (5
mmoles) was suspended in 6 ml of 3,4-dihydropyran. The
mixture was stirred at 4°C and supplemented with 60 mg of
pyridinium methane sulphonate; the mixture was then
heated to 50°C for 60 minutes. The mixture was cooled to
ambient temperature, supplemented with 30 ml of ethyl
acetate and extracted twice with 5 ml of water. The
aqueous phases were separated and discarded and the
organic phase was evaporated to dryness under vacuum.
After thorough drying in a high degree of vacuum, the
residue was dispersed cold with 5 ml of tert-butylmethyl

ether. The powdery solid thus obtained was separated by filtration, washed twice with 2 ml of tert-butylmethyl ether and finally dried in a high degree of vacuum. The yield of the reaction was 92%.

The product, the tetrahydropyranyl ether of N,N¹-bis(2-hydroxyethyl) nonandiamide had the following chemical-physical characteristics:

empirical formula:	C ₂₃ H ₄₂ N ₂ O ₆
formula weight:	442.60
elemental composition:	C=62.42%; H=9.57%; N=6.33%; O=21.69%
solubility in water:	10 mg/ml
solubility in organic solvents:	10 mg/ml in ethanol and DMSO
melting point:	55-57°C
TLC in acetonitrile/water (9:1):	R _f =0.56
TLC in toluene/ethanol/ acetic acid (65:30:5):	R _f =0.51

Example 13: Preparation of N-[2-(ethoxycarbonyl)oxyethyl] oleoylamide (OEA-EC)

3.3 g of N-(2-hydroxyethyl) oleoylamide (10 mmoles) was

10030061.0104083

dissolved in 75 ml of tetrahydrofuran (THF) with stirring. The solution was cooled to 4°C and supplemented with 1.11 g of N-methyl morpholine (11 mmoles) and 1.19 g of ethyl chloroformate (11 mmoles). The resulting mixture was kept at 4°C for 30 minutes with continuous stirring and then for a further 24 hours at ambient temperature. The mixture was then evaporated to dryness under vacuum. The residue was taken up with 50 ml of water and extracted 3 times with 30 ml of ethyl acetate; the organic phases were washed twice with 20 ml of water, recombined and evaporated to dryness. The residue was purified by preparative chromatography on silica gel with the use of a mixture of ethyl acetate and hexane in a ratio of 50:50, as the eluent. The fractions containing the product were recombined and evaporated to dryness. The oily residue was dried under a high degree of vacuum (yield 80%).

The product, N-[2-(ethoxycarbonyl)oxyethyl]oleoylamide had the following chemical and physical characteristics:

empirical formula:	$C_{23}H_{43}NO_4$
formula weight:	397.40
elemental composition:	C=69.48%; H=10.90%; N=3.52%; O=16.10%

solubility in water: slightly soluble
solubility in 10 mg/ml in ethanol,
organic solvents: ethyl acetate and
n-octanol

TLC in 100% ethyl acetate: $R_f=0.63$

TLC in heptane/isopropanol/
ethyl acetate/water

(40:20:50:2): $R_f=0.69$

Chemical and physical characteristics of the compounds of
the invention

The chemical and physical characteristics of the derivatives according to the invention were evaluated by quantitative measurement of the lipid/water partition parameter.

A useful parameter for evaluating the properties of a compound in relation to its possible absorption is in fact constituted by the coefficient of partition between the lipid phase and the aqueous phase, which is considered to be an expression of its lipophilicity and its degree of hydrophilicity. In general, it is commonly accepted that the greater the lipid/water partition

10030061.040404

coefficient is, the greater is the affinity for the cell membranes and hence the greater and quicker is the absorption. For the purpose of evaluating the characteristics of the derivatives of the invention, the partition parameter RM between the lipid and the aqueous phase, extrapolated from thin-film partition chromatography, was calculated; this parameter is commonly used to evaluate the lipophilic characteristics of compounds (Tomlinson E.J. Chromatogr. 1975, 113, 1) and is commonly used, for example, for local anaesthetics, in which a correlation has been shown between this parameter and biological activity (Bachrata M. et al. J. Chromatogr. 1979, 171, 29-36).

The partition parameter RM between the lipid phase and the aqueous phase was calculated both for the derivatives and for the non-substituted alkanolamides, from the Rf value obtained by thin-film chromatography on silica gel (particles of 2-2.5 μ moles, mean porosity 60 Å, thickness 0.25 mm on glass plate) in accordance with the formula:

$$RM = \log (1/R_f - 1)$$

and the ΔRM was obtained from the difference between the RM coefficients of the derivative and of the

corresponding alkanolamide. The results obtained were as follows:

Figure 1 shows the results of the first two experiments. In both cases, the results are consistent with the hypothesis that the system is able to learn the correct policy. The results of the third experiment are shown in Figure 2. The results are consistent with the hypothesis that the system is able to learn the correct policy.

Table I

compound Example No.	solvent 1			solvent 2		
	RF	RM	Δ RM	RF	RM	Δ RM
1	0.62	-0.213	-1.001	0.70	-0.368	-0.403
2	0.66	-0.288	-1.076	0.73	-0.432	-0.467
5	0.47	0.052	-0.736	0.65	-0.269	-0.304
6	0.40	0.176	-0.612	0.58	-0.140	-0.175
7	0.05	1.28	0.49	-	-	-
9	0.41	0.158	-0.630	0.62	-0.213	-0.247
11	0.43	0.122	0.666	0.65	-0.269	-0.304
3	0.61	-0.194	-1.020	0.68	-0.327	-0.397
13	0.63	-0.231	-0.984	0.69	-0.347	-0.365
4	0.75	-0.477	-0.866	0.52	-0.035	-0.723
10	0.52	-0.035	-0.424	0.44	0.105	-0.584
12	0.56	-0.105	-0.494	0.51	-0.017	-0.706

Solvent 1: 100% ethyl acetate

Solvent 2: heptane : isopropanol : ethyl acetate : H₂O

40:20:50:2

Solvent 3: acetonitrile : H₂O 9:1

Solvent 4: toluene : ethanol : acetic acid 65:30:5

It can be seen from the results obtained that the

covalent derivatives of the present invention surprisingly have a decidedly more marked lipophilic nature than the starting alkanolamides and hence more rapid absorption both at gastrointestinal level and topically. It should also be noted that, as already described in the prior art, substitutions on the alcoholic hydroxyl with carbamates and carbonates have already been investigated in order to improve the water-solubility of "hindered alcohols" but the resulting derivatives were found to be highly unstable (Safadi M. et al. Pharm. Res. 1993, 10, 1350-1355). The derivatives obtained by the invention, on the other hand, have been found, surprisingly, to possess very good lipo-solubility characteristics and have been found to be substantially stable. Water-solubility may, however, also be achieved by introducing substituents which can be ionized and which can thus be salified; compounds with good solubility in aqueous solvents are thus produced, this characteristic being particularly important both for ensuring absorption and for the administration of the pharmacological agent in aqueous solution, for example, by a parenteral route.

The demonstrated ability to substitute the hydrogen of the alcoholic residue of the alkanolamide with novel

substituents which can give stable covalent bonds with the oxygen forms part of the present invention.

Biological activity of the compounds of the invention

The compounds of the invention were tested with the use of biochemical tests in vitro which are described in the following biological examples. The compounds are identified on the basis of the number of the example given in the preceding chemical examples section above.

Example A

Effect of alkanolamide molecules on the binding of the synthetic ligands of the CB2 and CB1 cannabinoid receptors, respectively.

Rat RBL-2H3+ leukemic basophilic cells, which selectively express the cannabinoid CB2 receptor, and mouse N18TG2 neuroblastoma cells which selectively express the CB1 cannabinoid receptor were used. The cells were cultivated as described above (Facci L. et al. (1995) Proc. Natl. Acad. Sci. U.S.A., 92:: 3376-3380; Bisogno T. et al. 1997 J. Biol. Chem., 272: 3315-3323).

WIN 55,212.2 was used as the selectively agonist synthetic ligand for the CB2 receptor.

SR141716A was used as the selective antagonist for the CB1 receptor.

HU-210 was used as the selective antagonist for the CB2 receptor.

[³H]SR141716A (55 Ci/mmol) was supplied by Amersham; [³H]WIN55,212-2 (43 Ci/mmol) was supplied by NEN. The binding tests were performed with membranes of the cells resuspended in 50 mMol Tris pH 7.0 buffer; 2.5 mMol MgCl₂, 0.8 mMol EDTA; 0.05% bovine serum albumin (BSA); 0.01% ethanol, in the presence of 100 μM of phenyl-methyl-sulphonyl fluoride (PMSF-Sigma), with the use, of 300 pM of [³H]SR141716A and of [³H]WIN55,212-2, respectively, as the ligand.

The membranes were incubated for 90' at 30°C and filtered on glass microfibre filters (GFC-Whatman) and the radioactivity was detected by liquid scintillation. The specific binding was calculated with the use of either 10 μM SR141716A or 10 μM HU-210.

The K_i values were calculated by Chang-Prusoff's equation and expressed as concentration μM .

Table II

compounds	CB2 receptor	CB1 Receptor
	RBL-2H3+ cells	N18TG2 cells
	Lig. [^3H]WIN55,212-2	Lig. [^3H]SR141716A
	K_i (μM)	K_i (μM)
phenyl butazone	>15	>15
Comp. Example 4	0.002 ± 0.0009	>15
Comp. Example 6	0.001 ± 0.0008	>15
Comp. Example 1	0.006 ± 0.0018	>15
Comp. Example 7	0.009 ± 0.0025	>15

Example B

Effect of alkanolamide molecules on the stimulation of cyclic AMP (cAMP) by forskolin.

The tests were performed with the aim of checking whether the binding of the molecules of the present invention to the CB2 receptor has functional significance.

It is in fact known that the functional activation of the

CB2 receptor brings about, at intracellular level, inhibition of the enzymatic activity of adenylate cyclase and a reduction in the levels of the second-messenger cAMP, resulting in an increase in the conductance of the channels to potassium and an inhibition of proteic phosphorylation (Childers S.R. et al. Biochem. Pharmacol. 1996, 52: 819-827).

The dosages of cAMP were performed on RBL-2H3+ cells flowing together in Petri dishes with six wells (Falcon); the cells were stimulated for 10' at 37°C with 1 μ M of forskolin (Fluka) in 400 μ l of medium without serum, containing 20 mM HEPES, 0.1 mg/ml BSA and 0.1 mM 1-methyl-3-isobutyl xanthine (Sigma) and either ethanol or alkanolamide molecules with or without the addition of HU-210. After incubation, the cells were extracted and the levels of cAMP were evaluated with a suitable Amersham kit in accordance with the producer's method. The data were expressed in IC50 μ M.

Table III

Compounds Example No.	IC50 μ M
4	1.8
4 + HU-210 (0.5 μ M)	>20

6	1.9
6 + HU-210 (0.5 μ M)	>20

The covalent derivatives of the invention can thus usefully be used for the treatment of inflammatory processes, and also those with hyperalgesic components - both with a neurogenic basis and with an immunogenic basis - associated with immuno-inflammatory pathological conditions, and also autoimmune conditions, with neurodegenerative conditions associated with excitotoxic processes, as well as for conditions in which a non-psychomimetic effect of cannabinoids is known, all effects being attributable to an activity mediated by the CB2 receptor; amongst these, the following pathological conditions are mentioned by way of non-limiting example: neurological conditions such as, for example, multiple sclerosis, peripheral neuropathies - both somatic and autonomic - with various aetiologies, anoxic-ischaemic strokes and thromboses, cranial and spinal trauma, neurodegenerative conditions (AIDS - complex dementia, senile dementia, Alzheimer's syndrome, Parkinson's syndrome, amyotrophic lateral sclerosis), epilepsy, transitory ischaemic attacks (TIA) Huntington's chorea, retinal conditions with an anoxic-ischaemic basis, and also conditions secondary to glaucoma, headaches; viral

10030061.0104083

conditions with particular reference to conditions sustained by the propagation of so-called opportunistic viruses (such as, for example, the HIV virus), that is, viruses which can use the defence mechanisms of the organism itself to render its own propagation possible; skin conditions such as, for example psoriasis, atopic dermatitis and allergic dermatitis, lichen planus, dermatomyositis, scleroderma, pemphigus, pemphigoids, epidermolysis bullosa, discoid and systemic lupus erythematosus, heliodermatitis, indolent ulcers, hypertrophic scars, keloids, vulvar vestibulitis; conditions of the mucous membrane, such as, for example, oral lichen planus, stomatitis, acute and recurrent vaginitis, balanitis and balanoposthitis, and also conditions connected with inflammatory states of the accessory sex glands (prostate, vesical, seminal, etc.); respiratory conditions such as, for example, asthma, interstitial pulmonary fibrosis, allergic rhinitis; gastrointestinal conditions such as, for example, chronic inflammations of the mucosa; ophthalmic conditions such as, for example uveitis, uveoretinitis, Sjogren's syndrome, keratoconjunctivitis sicca, corneal ulcers, allergic and infectious conjunctivitis and giant papillary conjunctivitis, scar pemphigoids; joint conditions, such as, for example rheumatic arthritis,

10030061.0104083

rheumatoid arthritis, arthritis connected with psoriasis or with lupus, chronic arthritis and arthrosis, chondrodegeneration of traumatic, infectious and degenerative origin; cardiovascular conditions such as, for example, re-stenosis after angioplasty, atherosclerosis and cardiac ischaemic attacks, recurrence of episodes of infarction; specifically veterinary conditions such as, for example, conditions of the intervertebral disks in dogs and in horses, Stringhalt's syndrome, and laminitis in horses, skin, joint or connective-tissue conditions in horses, in dogs and in cats.

For the treatment of the above-mentioned conditions, the derivatives of the present invention may be administered by a parenteral systemic route (endovenously, intramuscularly, subcutaneously), a rectal route, or an oral route but also by a topical route (dermal and mucosal, ophthalmic, naso-pulmonary) and by a transdermal route. The dosages in which they are used may vary according to the administration route and to the seriousness of the disease and of the general condition of the patient. In any case, the expected therapeutic dosages are from 0.1 mg/die to 1 g/die for a period of between one week and three months of continued

administration. According to the chronic nature of the condition, the treatment may be repeated in various cycles.

The derivatives according to the invention may be administered in pharmaceutical compositions with excipients or diluents which are acceptable from the point of view of pharmaceutical use and are suitable for the purposes and in any case are such as to permit and/or to optimize absorption by the selected administration route. In particular, formulations in solution or suspension and also those produced with the use of preliminary micronization techniques and/or co-micronization with other active ingredients or with excipients for parental administration are envisaged; for the ophthalmic route, liquid forms as eye lotions and solid or semisolid forms as inserts, gels and ointments may be selected, and for oral administration they may be in the form of capsules, tablets, powders and pellets and also in gastroresistant formulations and may also be produced with the use of preliminary microencapsulation, liposomization and micellization techniques. For the topical routes, including the transdermal route, formulations as suppositories, micro-enemas, creams, ointments, sprays, gels, foams, dressings of various

thicknesses and patches may be used. All of the possible pharmaceutical forms indicated for the various administration routes may also be formulated with excipients or technological processes suitable for producing fast-release or slow-release medicaments with the derivatives of the invention.

It has also been found that the compounds of the present invention may also be used effectively as cosmetic ingredients having the function of conditioners and/or rheological additives. A further subject of the present invention is therefore the use of the compounds of formula (I) in cosmetics.

The invention is further described by the following non-limiting examples thereof; it is also possible to use other formulations produced with other ingredients and with other excipients for these purposes.

Example 14: ampoules for injection

Compound of Example 8	20 mg
sodium chloride	17 mg
water for injectables to make up to	2 ml

Example 15: lyophilized ampoules

Each lyophilized ampoule contains:

Compound of Example 6	30 mg
(co-micronized with mannitol)	
N-(4-hydroxy-3-methoxybenzyl)oleoyl amide	30 mg
(co-micronized with mannitol)	
mannitol	80 mg
each solvent ampoule contains:	
soya lecithin	40 mg
water for injectables to make up to	2 ml

Example 16: Tablets

Compound of Example 4, micronized	100 mg
lactose	100 mg
maize starch	70 mg
talc	8 mg
magnesium stearate	4 mg
carboxymethyl cellulose	8 mg

Example 17: capsules

Compound of Example 7	100 mg
-----------------------	--------

N-(4-hydroxy-3-methoxybenzyl)	
palmitoylamide	50 mg
maize oil	150 mg
gelatine FU	70 mg
glycerol FU	30 mg
titanium dioxide (E171)	0.5 mg
erythrosin (E127)	1 mg

Example 18: Eye lotion

Compound of Example 8	2 mg
benzalkonium chloride	1 mg
monobasic sodium phosphate hydrate	41 mg
dibasic sodium phosphate.12H ₂ O	249.5 mg
sodium edetate	10 mg
bi-distilled water to make up to	10 ml

Example 19: ophthalmic ointment

Compound of Example 4, micronized	100 mg
viscous white Vaseline to make up to	100 g

Example 20: skin cream

Compound of Example 4	100 mg
-----------------------	--------

hyaluronic acid	200 mg
sorbitan monostearate	500 mg
polyoxyethylene sorbitan monostearate	3 g
stearic acid	3 g
Vaseline oil	15 g
methyl ester of para-oxybenzoic acid	200 mg
ethyl ester of para-oxybenzoic acid	50 mg
demineralized water to make up to	100 g

Example 21: Vaginal gel

Compound of Example 7	150 mg
N-(4-hydroxy-3-methoxybenzyl)- palmitoylamide	100 mg
hyaluronic acid, sodium salt	100 mg
sodium alginate	2.5 g
glycerol	5 g
Bronopol	300 mg
demineralized water to make up to	100 g

Example 22: lotion for trichological use

Compound of Example 4	300 mg
propylene glycol	25 g
ethyl alcohol	50 g

demineralized water to make up to 100 g


Example 23: gel for dental use

Compound of Example 12	300 mg
hyaluronic acid	200 mg
(titrated in bio-binding epitope)	
carbomer	300 mg
sorbitol	20 g
methyl p-oxybenzoate	200 mg
ethyl p-oxybenzoate	50 mg
peppermint flavouring	1 g
demineralized water to make up to	100 g

10030061.0104083

CLAIMS

1. Compounds of the general formula (I):




their enantiomers, diastereoisomers, racemates and mixtures thereof, in which:

(a) R₁ may be


(1) a linear or branched alkyl radical, saturated or with from 1 to 6 double bonds, a monocyclic or polycyclic alkyl or alkenyl radical, or an aryl, arylalkyl or heterocyclic radical having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, acylamide, keto, nitro, alkoxy, halogen, mercapto, alkylthio, alkylldithio or arylldithio, -N⁺R₇R₈R₉ Z⁻ in which R₇, R₈ and R₉ are identical to one another or different and may be alkyl, alkenyl or arylalkyl radical, and Z⁻ is the anion of a pharmaceutically acceptable organic or inorganic acid;

(2) a group of formula (II):



in which R₄ is a linear or branched alkylene radical saturated or with from 1 to 6 double bonds, a cycloalkylene or cycloalkenylene radical, or an aryl, arylalkyl or heterocyclic diradical with one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, acylamide, keto, nitro, alkoxy, halogen, mercapto, alkylthio, alkylldithio, or arylldithio, R₅ and R₆ have the meanings given below for R₂ and R₃, respectively, or R₅ is a group of formula -Y-OH, where Y has the meaning described below in point (c);

(3) a group of formula (III):




in which R₄ has the meanings described above and R₁₀ is hydrogen or a linear or branched alkyl radical or an

arylalkyl radical, in which, when R10 is hydrogen, the resulting carboxylic group may optionally be salified with an organic or inorganic base to form a pharmaceutically acceptable salt;

(b) R2 is selected from hydrogen or an alkyl, alkenyl or arylalkyl radical;

(c) R3 is a group of formula (IV):




in which:

Y is a linear or branched alkylene radical, optionally substituted with one or more phenyl groups, possibly substituted with one or more hydroxy and/or alkoxy groups;

X is selected from:

(1) the radical of a cycloalkyl-ether or cycloalkylthio-ether with a ring of from 3 to 7 members, possibly substituted and possibly comprising a second heteroatom;


(2) a group of formula (V):



in which R₁₁ is selected from: a linear or branched alkyl or alkenyl radical, possibly containing from 1 to 5 heteroatoms, which may be identical to one another or different, a monocyclic or polycyclic alkyl radical, an arylalkyl radical, an aryl radical or a heterocyclic radical which is aromatic or completely or partially saturated, having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, amino, acylamino, keto, ureide, guanidino, nitro, alkoxy, halogen, -O-PO₃H₂, -O-PO₂H₂, -O-SO₃H, -SO₃H, mercapto, alkylthio, alkylldithio, arylldithio, azido, -NHR₉, -NR₇R₈, -N⁺R₇R₈R₉ Z⁻, in which Z⁻ is the anion of a pharmaceutically acceptable organic or inorganic acid and R₇, R₈ and R₉ are as defined above or R₇ and R₈ may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members, possibly containing other heteroatoms selected from oxygen, sulphur and nitrogen, the nitrogen possibly being substituted by an alkyl, benzyl or hydroxyethyl radical, and in which the basic and acid groups present

molecule may possibly be salified with organic or inorganic acids and bases, respectively, to form pharmaceutically acceptable salts;

(3) a group of formula (VI):



in which:


(i) R₁₂ is selected from: a linear or branched alkyl or alkenyl radical possibly containing from 1 to 5 heteroatoms which may be identical to one another or different, a mono- or polycyclic alkyl radical, an arylalkyl radical, an aryl radical or a heterocyclic radical which is aromatic or completely or partially saturated, having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, amino, acylamino, keto, ureide, guanidino, nitro, alkoxy, -O-C₆H₄-W, halogen, -O-PO₃H₂, -O-PO₂H₂, -O-SO₃H, -SO₃H, mercapto, alkylthio, alkylthio, arylthio, azido, -NHR₉, -NR₇R₈, -N⁺R₇R₈R₉ Z⁻, in which Z⁻ is the anion of a pharmaceutically acceptable organic

10030551.0104083

or inorganic acid, and R7, R8 and R9 are as defined above or R7 and R8 may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members, possibly containing other heteroatoms selected from oxygen, sulphur and nitrogen, possibly substituted with an alkyl, benzyl or hydroxyethyl radical, in which W is selected from hydrogen, alkyl, alkoxy, nitro, halogen, and hydroxy, and in which the basic and acid groups present in the molecule may possibly be salified with organic or inorganic acids and bases, respectively, to form pharmaceutically acceptable salts;

R13 has, independently, the meanings of R12, or may be hydrogen;


(4) a group of formula (VII):



in which R14 is selected from: a linear or branched alkylene or arylalkylene radical, possibly substituted with a hydroxy group or -O-CO-R15, in which R15 is an alkyl, alkenyl or arylalkyl radical, R7, R8 and R9 are as

defined above, or R7 and R8 may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members as defined above, and Z^- is a pharmaceutically acceptable inorganic or organic anion;

(5) a group of formula (VIII):



in which the $-SO_3^-$ group may be in the ortho, meta or para position relative to the keto group, and M^+ is a pharmaceutically acceptable inorganic or organic cation.

2. Compounds according to Claim 1 in which R2 and R5 are identical to one another.

3. Compounds according to Claim 1 or Claim 2, in which R3 and R6 are identical to one another.

4. Compounds according to any one of Claims 1 to 3 in which

R1 is a saturated or mono-unsaturated alkyl radical with from 1 to 23 carbon atoms, preferably from 13 to 15

carbon atoms.

5. Compounds according to any one of Claims 1 to 4, in which

R4 is a saturated or mono-unsaturated alkylene radical with from 1 to 20 carbon atoms, preferably from 6 to 14 carbon atoms.

6. Compounds according to any one of Claims 1 to 5, in which R7, R8 and R9 are an alkyl or alkenyl radical with from 1 to 7 carbon atoms, preferably a methyl group.

7. Compounds according to any one of Claims 1 to 6, in which

R10 is an alkyl radical with from 1 to 20 carbon atoms.

8. Compounds according to any one of Claims 1 to 7, in which

R2 is an alkyl or alkenyl group with from 1 to 7 carbon atoms.

9. Compounds according to any one of Claims 1 to 8, in which

Y is an alkylene radical with from 2 to 20 carbon atoms, preferably from 2 to 6 carbon atoms.

40030061-0104083

10. Compounds according to any one of Claims 1 to 9, in which, when X is a cycloalkyl-ether or thio-ether, it has a ring with 5 or 6 members, preferably selected from tetrahydropyran-2-yl, tetrahydrofuran-2-yl, tetrahydrothiopyran-2-yl, tetrahydrothiofuran-2-yl, 4-methoxytetrahydropyran-2-yl, or 1,4-dioxan-2-yl.

11. Compounds according to any one of Claims 1 to 10, in which R11 or R12 are an alkyl or alkenyl radical with from 1 to 25 carbon atoms possibly containing from 1 to 5 heteroatoms selected from sulphur, oxygen and nitrogen.

12. Compounds according to any one of Claims 1 to 11, in which R7 and R8 form, together with the nitrogen atoms to which they are bound, a ring having from 5 to 7 members, possibly containing a further nitrogen atom which is non-substituted or is substituted by a methyl or ethyl group.

13. Compounds according to any one of Claims 1 to 12, in which the -NR12R13 group is selected from piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl and hydroxyethylpiperazinyl groups.

14. Compounds according to any one of Claims 1 to 13, in

which R14 is an alkylene radical with from 1 to 10 carbon atoms, preferably from 2 to 4 carbon atoms.

15. Compounds according to any one of Claims 1 to 14, in which R15 is an alkyl or alkenyl radical with from 1 to 7 carbon atoms.

16. Compounds according to any one of Claims 1 to 15 for use as medicaments.

17. Compounds according to Claim 16, for use as drugs with agonist activity in relation to the CB2 cannabinoid receptors.

18. Compounds according to Claim 17, for use, alone or in association with functional agonists of the peripheral CB1 receptor, as drugs for the treatment of inflammatory processes, and also those with a hyperalgetic component, both with a neurogenic basis and with an immunogenic basis, associated with immuno-inflammatory and neurodegenerative pathological conditions and pathological conditions in which a non-psychomimetic effect of cannabinoids mediated either by CB2 receptors or by peripheral CB1 receptors is noted.

19. Use of the compounds according to anyone of Claims 1 to 15 as cosmetic additives.

10030061.010402

DECLARATION AND POWER OF ATTORNEY

Attorney Docket No.: 13170PCTUS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor"

the specification of which:

(check one)

☐ is attached hereto

☐ was filed on

as Application Serial No.

and was amended on

(if applicable)

☒ was described and claimed in

PCT International Application No. PCT/IT99/00207 filed on July 7, 1999

and was amended on

under PCT Article 19 (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulation, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the of the application on which priority is claimed:

Prior Foreign Application(s) Priority Claimed

			Priority Claimed	
<u>PCT/IT99/00207</u>	<u>PCT</u>	<u>July 7, 1999</u>	<input checked="" type="checkbox"/> <input type="checkbox"/>	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/> <input type="checkbox"/>	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/> <input type="checkbox"/>	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

100 Full name of (first) inventor: COMELLI Cristina

Inventor's

Signature: Cristina Comelli

Date: December 28, 2001

Residence: PADOVA - Italy ITK

Citizenship: Italian

Post Office Address: Via dei Mille, 24 - 35141 PADOVA - Italy

200 Full name of second inventor: DELLA VALLE Francesco

Inventor's

Signature: Francesco Della Valle

Date: December 28, 2001

Residence: PADOVA - Italy ITK

Citizenship: Italian

Post Office Address: Via Cerato, 14 - 35122 PADOVA - Italy

300 Full name of second inventor: DELLA VALLE Maria Federica

Inventor's

Signature: Maria Federica Della Valle

Date: December 28, 2001

Residence: PADOVA - Italy ITK

Citizenship: Italian

Post Office Address: Via Lepanto, 9 - 35141 PADOVA - Italy

400 Full name of second inventor: MARCOLONGO Gabriele

Inventor's

Signature: Gabriele Marcolongo

Date: December 28, 2001

Residence: DUE CARRARE (Padova) - Italy ITK

Citizenship: Italian

Post Office Address: Via Strade Interne, 3 - 35020 DUE CARRARE (Padova) - Italy